Plasma Cystatin C and Acute Kidney Injury

Use of Cystatin C in Predicting AKI in Patients Undergone Cardiopulmonary Bypass Surgery

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01652755

Enrollment

100

Registered

2012-07-30

Start date

2011-04-30

Completion date

2013-05-31

Last updated

2012-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Keywords

cystatin C,acute kidney injury,

Brief summary

To evaluate the utility of plasma cystatin C(pCysC) as a predictive and diagnostic marker of acute kidney injury(AKI) in patients undergone cardiopulmonary bypass surgery.

Detailed description

This is a prospective AKI observational study in patients undergone cardiopulmonary bypass surgery. pCysC and plasma creatine will be measured at entry to ICU.AKI was defined as 50% increase in plasma creatine above baseline.The predictive and diagnostic performance of pCysC will be assessed from area under receiver operator characteristic curve(AUC) and odds ratio(OR).

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* patients with CPB and admitted to ICU

Exclusion criteria

* patients with the age \>80 or \<18 years * with preexisting renal dysfunction

Countries

China

Contacts

Primary ContactHongying Ni, MM

nihongying2@163.com86

Outcome results